As a result of the high demand for GlaxoSmithKline's new shingles vaccine, Shingrix, two U.S. senators have urged the pharma giant to boost inventory levels on facing a shortage in the supplies even after the company established their "fair and equitable" process to ship Shingrix doses.
Order limits have been introduced by GSK owing to high demand for the product, as per a note on the CDC’s website. In the meantime, shipping delays are being experienced by providers and according to the CDC, the delays are likely to remain throughout the year.
GlaxoSmithKline plc (GSK,GSK.L) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion recommending marketing authorisation for Shingrix (RELATED: CDC backs GSK’s Shingrix over Merck & Co’s Zostavax) for the prevention of shingles, or herpes zoster, and post-herpetic neuralgia or PHN
GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.
Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot—and it's a key piece of CEO Emma Walmsley's prescription for growth at the drugmaker.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.